Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus Arrhythmias, Cardiac Atrial Fibrillation Atrial Fibrillation (AF) Cardiovascular Diseases Endocrine System Diseases Glucose Metabolism Disorders Heart Diseases Metabolic Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Bursa Yüksek İhtisas Hastanesi

Bursa, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients > 18 years and < 90 years,
Patient diagnosed with DM
Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm

Exclusion criteria

patient who are not suitable for anticoagulant use,
have thyroid dysfunction,
glomerular filtration rate ≤ 25 ml/min/1.73 m²,
patients whose sinus rhythm cannot be achieved with electrical cardioversion,
malignancy patients,
patients with acute or chronic inflammatory disease,
patients with peripheral artery disease,
patients with pacemakers,
patients with advanced valve stenosis or insufficiency,
patients who have had coronary bypass surgery,
patients with percutaneous or surgical bioprosthesis or metallic valve surgery.

Treatment and study plan

Primary outcomes

Atrial fibrillation recurrence

Time frame: six month

Sponsors and collaborators

Lead sponsor

Bursa Postgraduate Hospital

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2024
First posted: Apr 30, 2025
Registry last updated: Jun 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting